BiotechTube

rituximab

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diffuse Large B-Cell Lymphoma

Conditions

Diffuse Large B-Cell Lymphoma

Trial Timeline

Feb 1, 2012 → Feb 1, 2013

NCT ID
NCT01534949

About rituximab

rituximab is a phase 1 stage product being developed by Celltrion for Diffuse Large B-Cell Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01534949. Target conditions include Diffuse Large B-Cell Lymphoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT01534949Phase 1Terminated
NCT01534884Phase 1Completed

Competing Products

20 competing products in Diffuse Large B-Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
IVA337 + PlaceboInventivaPhase 2
47
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)Eli LillyPhase 2
52
YM155Astellas PharmaPhase 2
52
enzastaurin + gemcitabine + rituximab + oxaliplatinEli LillyPhase 2
52
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6Johnson & JohnsonPhase 2
52
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + VincristineJohnson & JohnsonPhase 2
52
Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + GemcitabineAbbViePhase 3
77
ABBV-525AbbViePhase 1
33
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + EpcoritamabAbbViePhase 1/2
41
Copanlisib + VenetoclaxAbbViePhase 1/2
41
Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
77
Epcoritamab + LenalidomideAbbViePhase 2
52
Venetoclax + SelinexorAbbViePhase 1
33
EpcoritamabAbbViePhase 1
33
Loncastuximab Tesirine and EpcoritamabAbbViePhase 2
52
Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
77
bendamustine + navitoclax + rituximabAbbViePhase 2
52
EpcoritamabAbbViePhase 2
52
Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomideAbbViePhase 1/2
41
Epcoritamab + IbrutinibAbbViePhase 1/2
41

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85